The Peptide-based Gastrointestinal Disorders Therapeutics market is increasing due to the rising prevalence of gastrointestinal issues, growing demand for targeted and personalized treatments, and increased research and development investments from pharmaceutical companies. North America is anticipated to lead the market due to the vast patient pool and developed healthcare infrastructure. Major players in the market include Takeda Pharmaceutical Company, GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, and Novo Nordisk, as well as Shire Plc, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Allergan Plc, and Accredo Health Group, Inc.